Association between mutant IDHs and tumorigenesis in gliomas

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


To become immortalized, cells need to maintain the telomere length via the activation of telomerase or alternative lengthening of telomere. Mutations in IDH1/2 are strongly associated with the early stage of gliomagenesis. Previous work has shown that the accumulation of 2-HG, which is induced by mutant IDH1/2, inhibits α-KG-dependent deoxygenase and leads to genome-wide histone and DNA methylation alterations. These alterations are believed to contribute to tumorigenesis. H-Ras can transform human astrocytes with the inactivation of p53/pRb and expression of hTERT; however, mutant IDH1 can also transform cells. Moreover, mutant IDH1 can drive the immortalization and transformation of p53-/pRb-deficient astrocytes by reactivating telomerase and stabilizing telomeres in combination with increased histone lysine methylation and c-Myc/Max binding at the TERT promoter. It remains unclear whether mutant IDH1/2 acts only as the initial driver of gliomagenesis or it maintains transformed cells. Clinical studies are being performed to assess the use of mutant IDH1/2 inhibitors for treating gliomas.

Original languageEnglish
Pages (from-to)194-198
Number of pages5
JournalMedical Molecular Morphology
Issue number4
Publication statusPublished - 01-12-2018

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology


Dive into the research topics of 'Association between mutant IDHs and tumorigenesis in gliomas'. Together they form a unique fingerprint.

Cite this